Showing results (2161-2170 of 2,925) with videos related to

Sort By:
Pageof 293
Investigational New Drugs|April 21, 2017
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumorsJeffrey R Infante, Roger B Cohen, Kevin B Kim, et al.
The Spine Journal : Official Journal of the North American Spine Society|March 16, 2021
Caudally directed upper-instrumented vertebra pedicle screws associated with minimized risk of proximal junctional failure in patients with long posterior spinal fusion for adult spinal deformityAndrew B Harris, Floreana N Kebaish, Varun Puvanesarajah, et al.
Orthopedics|October 3, 2012
Inter- and intraobserver reliability of the radiographic diagnosis and treatment of acromioclavicular joint separationsMatthew J Kraeutler, Gerald R Williams, Steven B Cohen, et al.
Plos Pathogens|November 27, 2023
Assessing vaccine-mediated protection in an ultra-low dose Mycobacterium tuberculosis murine modelCourtney R Plumlee, Holly W Barrett, Danica E Shao, et al.
JACC. Advances|August 5, 2026
Prediabetes, Malignant Left Ventricular Hypertrophy, and Risk of Incident Heart Failure Among Hypertensive AdultsArnaud D Kaze, Stephen P Juraschek, Jordana B Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2014
A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancerA Jimeno, K Shirai, M Choi, et al.
Cancer Research|August 17, 2002
Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor alpha allele in the prostate epitheliumJiapeng Huang, William C Powell, Ani C Khodavirdi, et al.
BMC Cancer|March 8, 2017
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumorsPatricia M LoRusso, Jeffrey R Infante, Kevin B Kim, et al.
Expert Review of Molecular Diagnostics|December 23, 2021
Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-ɑ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritisVibeke Strand, Stanley B Cohen, Jeffrey R Curtis, et al.
Frontiers in Microbiology|September 20, 2021
Metagenomic Insights Into the Microbial Iron Cycle of Subseafloor HabitatsArkadiy I Garber, Ashley B Cohen, Kenneth H Nealson, et al.
Pageof 293